DETAILS

Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID	DDPD00339
Drug Name	Pyrazinamide
Molecular Weight	123.1127
Molecular Formula	C5H5N3O
CAS Number	98-96-4
SMILES	NC(=O)C1=NC=CN=C1
External Links
	DRUGBANK	DB00339
	PubChem Compound	1046
	PDR	788
	Drugs.com	Drugs.com Drug Page

Experimental Physicochemical Property

Property Name	Property Value	Unit	Raw Value	Raw Unit	Reference
Log P	-0.6	-	-0.6	-	HANSCH,C ET AL. (1995)
Melting Point	192.0	℃	192	℃	PhysProp
Water Solubility	15000.0	mg/L	15000	mg/L	MERCK INDEX 1996)
pKa	-0.5	-	-0.5	-	DRUGBANK
Log S	-0.91	-	-0.91	-	ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Factor	Reference
C Max	35000.0	ng/ml	35(19-103)	mcg/ml	PO, oral;		The Pharmacological Basis of Therapeutics
T Max	1.5	h	1-2	h	PO, oral;		The Pharmacological Basis of Therapeutics
Clearance	0.0660	L/h/kg	1.1(0.2-2.3）	ml/min/kg	apparent clearance; tuberculosis; Male, men; Female, women; adults;	Children ↑ ;	The Pharmacological Basis of Therapeutics
Volume of Distribution	0.57	L/kg	0.57（0.13-1.04）	L/kg	Apparent volume of distribution; tuberculosis; Male, men; Female, women; adults;		The Pharmacological Basis of Therapeutics
Half-life	9.5	h	9-10	h	normal,healthy;		DRUGBANK
Half-life	6.0	h	6(2-23)	h		Children ↓ ;	The Pharmacological Basis of Therapeutics
Eliminate Route	70.0	%	~70	%	Urinary excretion; PO, oral;		DRUGBANK
Eliminate Route	9.0	%	4-14	%	Urinary excretion; PO, oral; adults; tuberculosis; human, homo sapiens; Unchanged drug;		The Pharmacological Basis of Therapeutics
Protein Binding	10.0	%	~10	%	plasma proteins;		DRUGBANK
Protein Binding	10.0	%	10	%			The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name	Property Value	Unit	Raw Value	Raw Unit	Annotation	Frequency	Brand Name	Component	Reference
Max dose for infants	40.0	mg/kg/day	40	mg/kg/dose	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for infants	2.0	g/dose	2	g/dose	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for infants	50.0	mg/kg/dose	50	mg/kg/dose	PO, oral; 3 days/week	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for infants	3.0	g/dose	3	g/dose	PO, oral; 3 days/week		Pyrazinamide	pyrazinamide	PDR
Max dose for infants	4.0	g/dose	4	g/dose	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for children	40.0	mg/kg/day	40	mg/kg/dose	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for children	2000.0	mg/dose	2	g/dose	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for children	21.4285714285714	mg/kg/day	50	mg/kg/dose	PO, oral; 3 days/week	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for children	3000.0	mg/dose	3	g/dose	PO, oral; 3 days/week		Pyrazinamide	pyrazinamide	PDR
Max dose for children	4000.0	mg/dose	4	g/dose	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for adolescents	40.0	mg/kg/dose	40	mg/kg/dose	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adolescents	2000.0	mg/dose	2	g/dose	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adolescents	50.0	mg/kg/dose	50	mg/kg/dose	PO, oral; 3 days/week	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for adolescents	1285.71428571429	mg/dose	3	g/dose	PO, oral; 3 days/week		Pyrazinamide	pyrazinamide	PDR
Max dose for adolescents	1142.85714285714	mg/dose	4	g/dose	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	30.0	mg/kg/day	30	mg/kg/dose	PO, oral	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	3000.0	mg/dose	3	g/dose	PO, oral	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	75.0	mg/kg/dose	75	mg/kg/dose	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	2000.0	mg	2	g	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	3000.0	mg	3	g	PO, oral; 3 days/week		Pyrazinamide	pyrazinamide	PDR
Max dose for adults	4000.0	mg	4	g	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	1500.0	mg	1.5	g	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	2500.0	mg	2.5	g	PO, oral; 3 days/week		Pyrazinamide	pyrazinamide	PDR
Max dose for adults	3000.0	mg	3	g	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	1000.0	mg	1	g	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for adults	1500.0	mg	1.5	g	PO, oral; 3 days/week		Pyrazinamide	pyrazinamide	PDR
Max dose for adults	2000.0	mg	2	g	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	30.0	mg/kg/dose	30	mg/kg/dose	PO, oral	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	3000.0	mg/day	3	g/dose	PO, oral	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	75.0	mg/kg/dose	75	mg/kg/dose	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	2000.0	mg	2	g	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	3000.0	mg	3	g	PO, oral		Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	4000.0	mg	4	g	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	1500.0	mg	1.5	g	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	2500.0	mg	2.5	g	PO, oral		Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	3000.0	mg	3	g	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	1000.0	mg	1	g	PO, oral; 5 days/week	qd	Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	1500.0	mg	1.5	g	PO, oral		Pyrazinamide	pyrazinamide	PDR
Max dose for geriatric	2000.0	mg	2	g	PO, oral	biw	Pyrazinamide	pyrazinamide	PDR

Drug Property Radar Chart

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1